ClinicalTrials.Veeva

Menu

Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma. (MYELOME-PA)

N

Nantes University Hospital (NUH)

Status

Terminated

Conditions

Multiple Myeloma in Older Patients

Treatments

Other: Vulnerability and therapeutic changes in older patients with multiple myeloma.

Study type

Interventional

Funder types

Other

Identifiers

NCT02063113
RC13_0437

Details and patient eligibility

About

The aim of this study is to determine whether the presence of vulnerability detected by geriatricians is associated with treatment discontinuation in older patient. During the comprehensive geriatric assessment realized before the decision-treatment, the following data are recorded and their impact in the therapeutic changes will also be analysed: comorbidity, age, depression, functional status, the cognitive impairment and malnutrition.

Enrollment

48 patients

Sex

All

Ages

70 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients aged 70 years and older
  • Patients referred for a assessment of a newly diagnosed multiple myeloma
  • Patients for who the initial therapy proposed is either melphalan-prednisone-thalidomide or melphalan-prednisone-bortezomib or included in a phase 3 trial.
  • Patients who provide informed written consent

Exclusion criteria

  • Patients who refuse the study
  • Patients who won't have therapy
  • Patients can't respond to geriatric assessment because of severe cognitive disorder
  • Patients with a legal guardian

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

48 participants in 1 patient group

NA/NA
No Intervention group
Treatment:
Other: Vulnerability and therapeutic changes in older patients with multiple myeloma.

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems